Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336098 · ClinicalTrials.gov registry record · Phase 1
Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04336098 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 85 participants.
The verdict
NCT04336098, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
- DRUG Albumin-Bound Paclitaxel
- DRUG SRF617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-03-16 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04336098
The ClinicalTrials.gov registry entry for NCT04336098 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04336098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04336098 about?
NCT04336098 is a clinical study titled "Study of SRF617 in Patients With Advanced Solid Tumors". A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
What is the current status of trial NCT04336098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-03-16. Estimated completion is 2023-08-25.
What interventions are being tested in trial NCT04336098?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG), Albumin-Bound Paclitaxel (DRUG), SRF617 (DRUG).
Who is sponsoring clinical trial NCT04336098?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.